Diagnostics
Excerpt from the Press Release: PHILADELPHIA, PA / ACCESS Newswire / May 20, 2026 / Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, announced the publication of a recently completed study entitled Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death…
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing…
Excerpt from the Press Release: SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2…
Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in…
Findings from the GUARDIAN-Lung Registry highlight statistically significant reductions in hospital readmissions and acute rejection rates with advanced hypothermic lung preservation technologies Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45th ISHLT Annual Meeting and Scientific Sessions.…
Excerpt from the Press Release: FOSTER CITY, Calif. and DURHAM, N.C., April 24, 2025 /PRNewswire/ — 1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect…
Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head…
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 14, 2025– Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)…
Presentation highlights preclinical profile for HST-1021, a highly differentiated potent, selective, and potential first-in-class MALT1 scaffolding inhibitor Excerpt from the Press Release: BOSTON, June 20, 2024 /PRNewswire/ — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,”…
Excerpt from the Press Release: BERKELEY, Calif. and MAINZ, Germany, April 25, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz…